Newfoundland and Labrador is the latest Canadian province to implement a biosimilar switching policy, following in the footsteps of Ontario and 7 other jurisdictions.
Newfoundland and Labrador has become the latest Canadian province to implement a biosimilar switching policy requiring patients to be prescribed a biosimilar over a reference product, according to an announcement from Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry.
“Biosimilars Canada and its member companies congratulate Health and Community Services Minister Tom Osborne and the Government of Newfoundland and Labrador for implementing a biosimilars switching policy to help support the long-term sustainability of the province’s public drug program,” Jim Keon, president of Biosimilars Canada, said in a statement.
The policy gives providers a until March 31, 2024, to prepare and educate patients currently treated on a reference product on the benefits of biosimilars to ease them into transitioning to a new product. New patients will automatically be prescribed a biosimilar. The policy will also allow the Newfoundland and Labrador Public Drug Program (NLPDP), the public health plan for the province, to invest in new and innovative therapies while continuing to expand access to existing drug therapies.
Under the initiative, beneficiaries currently using originator Copaxone (glatiramer acetate), Enbrel (etanercept), Humalog (insulin lispro), Humira (adalimumab), Lantus (insuling glargine), Lovenox (enoxaparin sodium), NovoRapid (insulin aspart), Remicade (infliximab), and Rituxan (rituximab) will be transitioned to a safe, effective and less costly biosimilar version. If a patient does not want to transition to a biosimilar, they risk losing coverage.
Newfoundland and Labrador is the ninth Canadian jurisdiction to implement a biosimilar transitioning policy, following British Columbia, Nova Scotia, New Brunswick, Saskatchewan, Quebec, the Northwest Territories, Alberta, and Ontario (Figure).
There are 9 Canadian jurisdictions with a biosimilar switching policy. Four (Nunavut, Manitoba, Yukon, and Prince Edward Island) do not.
The topic of switching or transitioning patients from a reference product to a biosimilar has raised concerns about whether product transitions will alter safety or efficacy outcomes. However, no province with a switching policy has experienced impacts on clinical outcomes and both the European Union and United Kingdom have declared all biosimilars as interchangeable with their reference products.
In its statement, Biosimilars Canada shared a quote from Health Canada’s biosimilar drug fact sheet on the safety of switching from a reference product to a biosimilar: “Patients and health care providers can have confidence that biosimilars are effective and safe for each of their authorized indications, and that no differences are expected in efficacy and safety following a change in routine use between a biosimilar and its reference biologic drug in an authorized indication.”
Biosimilars Canada commented saying that the full benefits of biosimilars, including their savings potential, won’t be realized unless drug plans adopt policies that support the expanded use of biosimilars, such as transitioning policies.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.